FindTrial
Sign In

Clinical trial to study the effect of Budesonide taken through inhalation in mild COVID cases

Inhalation Budesonide in the treatment of patients with mild Covid-19

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/10/028581
Enrollment
1000
Registered
2020-10-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Budesonide, Local standard of care: Budesonide Rotacaps 200 mcg BD for 10 - 14 days depending on onset of symptoms given in addition to the local standard of care Intervention2: BUDESON

Sponsors

Dr Tushar Patel
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient with RT-PCR OR Rapid Antigen confirmed diagnosis of Covid-19. asymptomatic Patent with mild symptoms of less than 5 days duration. 3.Spo2 >94% at room air. 4.No Radiological evidence of Pneumonia. 5 Patient aged >18years to 99Years.

Exclusion criteria

Exclusion criteria: 1. Patient requiring hospitaisation. 2. Patient unable to take the drug as drirected and comply with study procedure. 3.Vulnerable population(Pregnant women,Lactating women,Prisoners,Unable to consent). 4 Patients on Systemic/Inhalational Steroids.

Design outcomes

Primary

MeasureTime frame
HospitalizationTimepoint: 10 - 14 days depending on the onset of symptoms—

Secondary

MeasureTime frame
noTimepoint: no—

Countries

India

Contacts

Public ContactDr Tushar Patel

GCS Medical College, Ahmedabad

drtusharpatel@yahoo.com985082672

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026